A Phase 1 Open-label First-in-human Dose-escalating Safety and Tolerability Study Evaluating Subcutaneous Administration of Andes-1537 for Injection in Patients With Advanced Unresectable Solid Tumors That Are Refractory to Standard Therapy or For Which No Standard Therapy is Available
Latest Information Update: 24 Oct 2018
At a glance
- Drugs Andes 1537 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Andes Biotechnologies
- 16 Oct 2018 Status changed from recruiting to discontinued.
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 18 Jan 2018 Planned End Date changed from 1 Jul 2018 to 1 Dec 2018.